Literature DB >> 32361874

A non-diploid DNA status is linked to poor prognosis in renal cell cancer.

Franziska Büscheck1, Christoph Fraune1, Martina Kluth1, Maximilian Lennartz1, Ronald Simon2, Claudia Hube-Magg1, Christian Morlock1, Silvano Barbieri1, Carolin Wahl1, Christian Eichelberg3, Christina Möller-Koop1, Doris Höflmayer1, Corinna Wittmer1, Waldemar Wilczak1, Guido Sauter1, Margit Fisch4, Till Eichenauer4, Michael Rink4.   

Abstract

PURPOSE: DNA ploidy measurement has earlier been suggested as a potentially powerful prognostic tool in many cancer types, but the role in renal tumors is still unclear.
METHODS: To clarify its prognostic impact, we analyzed the DNA content of 1320 kidney tumors, including clear cell, papillary and chromophobe renal cell carcinoma (RCC) as well as renal oncocytoma and compared these data with clinico-pathological parameters and patient prognosis.
RESULTS: A non-diploid DNA content was seen in 37% of 1276 analyzable renal tumors with a striking predominance in chromophobe carcinoma (74.3% of 70 cases). In clear cell carcinoma, a non-diploid DNA content was significantly linked to high-grade (ISUP, Fuhrman, Thoenes; p < 0.0001 each), advanced tumor stage (p = 0.0011), distant metastasis (p < 0.0001), shortened overall survival (p = 0.0010), and earlier recurrence (p < 0.0001). In papillary carcinoma, an aberrant DNA content was significantly linked to high Fuhrman grade (p = 0.0063), distant metastasis (p = 0.0138), shortened overall survival (p = 0.0010), and earlier recurrence (p = 0.0003).
CONCLUSION: In summary, the results of our study identify a non-diploid DNA content as a predictor of an unfavorable prognosis in clear cell and papillary carcinoma.

Entities:  

Keywords:  DNA ploidy; Flow cytometry; Prognosis; Renal cell cancer

Year:  2020        PMID: 32361874      PMCID: PMC7969487          DOI: 10.1007/s00345-020-03226-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  88 in total

1.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:  Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

Review 2.  Oncology applications of flow cytometry.

Authors:  Y O Huh; L Huck
Journal:  Clin Lab Sci       Date:  1992 Jan-Feb

Review 3.  Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors.

Authors:  D E Merkel; W L McGuire
Journal:  Cancer       Date:  1990-03-01       Impact factor: 6.860

Review 4.  Prognostic value of deoxyribonucleic acid content in prostate cancer: a review of current results.

Authors:  J Adolfsson
Journal:  Int J Cancer       Date:  1994-07-15       Impact factor: 7.396

5.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

Review 6.  Clinical applications of image cytometry to human tumour analysis.

Authors:  C Millot; J Dufer
Journal:  Histol Histopathol       Date:  2000-10       Impact factor: 2.303

Review 7.  Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Authors:  Håvard E Danielsen; Manohar Pradhan; Marco Novelli
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 8.  Clinical application of flow cytometry to urological malignancies.

Authors:  M Tachibana
Journal:  Keio J Med       Date:  1996-06

Review 9.  DNA content in human cancer. Application in pathology and clinical medicine.

Authors:  D Seckinger; E Sugarbaker; O Frankfurt
Journal:  Arch Pathol Lab Med       Date:  1989-06       Impact factor: 5.534

Review 10.  Renal cell carcinoma.

Authors:  Eric Jonasch; Jianjun Gao; W Kimryn Rathmell
Journal:  BMJ       Date:  2014-11-10
View more
  2 in total

1.  Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma.

Authors:  Till Eichenauer; Navid Shadanpour; Martina Kluth; Cosima Göbel; Sören Weidemann; Christoph Fraune; Franziska Büscheck; Claudia Hube-Magg; Christina Möller-Koop; Roland Dahlem; Margit Fisch; Michael Rink; Silke Riechardt; Eike Burandt; Christian Bernreuther; Sarah Minner; Ronald Simon; Guido Sauter; Waldemar Wilczak; Till Clauditz
Journal:  World J Surg Oncol       Date:  2020-06-13       Impact factor: 2.754

2.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.